Cyteir was focused on developing synthetic lethal therapies that target specific genetic vulnerabilities in cancer cells, aiming to enhance treatment efficacy while minimizing damage to healthy tissues. The company sought to address the limitations of traditional cancer therapies by providing more precise and effective treatment options for patients with specific genetic profiles.
Funding
$80M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cyteir was focused on developing synthetic lethal therapies that target specific genetic vulnerabilities in cancer cells, aiming to enhance treatment efficacy while minimizing damage to healthy tissues. The company sought to address the limitations of traditional cancer therapies by providing more precise and effective treatment options for patients with specific genetic profiles.
Features
Feature details are not available yet.